Scott Rocklage, Ph.D. is the Managing Partner at the investing firm 5AM Ventures. He first joined this company, which specializes at investing in early stage biotechnology companies, in 2003 as a Venture Partner and earned his present position the very next year. He brought a wealth of experience with him into this position as he had a very successful career in the industry himself.
Dr. Scott Rocklage holds a Bachelor’s of Science in Chemistry which he earned at the University of California, Berkeley. He then attended MIT in Boston, MA and earned his Ph.D. in Chemistry. While at MIT his research was conducted in the same lab as Richard Schrock who would, later on, win a Nobel Prize in Chemistry.
Dr. Rocklage has a wealth of experience in the biotechnology industry and has served in executive level positions for a variety of companies. He also has experience in research and development. His first two positions in the industry were in R&D with two companies, Catalytica and Salutar.
After working in R&D for a number of years, Dr. Scott Rocklage entered the executive ranks. Has been both the President and CEO of Nycomed Salutar. He was also the CEO and Chairman of another biotechnology firm, Cubist Pharmaceuticals. Additionally, he has been on the board of several companies including as chairman. Some of these include Ilypsa, Semprus, Miikana, Kinestarl, Cidara, and Rennovia.
As a leader in the biotechnology industry, Dr. Scott Rocklage holds more than 30 U.S. patents. He has also published over 100 research papers which have been published in a number of peer-reviewed publications and has been cited in other research studies. Three products he has been strategically involved with acquired FDA approval. These were Cubicin, Teslascan, and Omniscan.
One of the new trends in the biotechnology industry that Dr. Rocklage is particularly excited about is the new targeted cancer drugs. Conventional ways of treating cancer are chemotherapy, radiation, surgery, and conventional drugs which kill both healthy and diseased cells. Read more: Scott Racklage | Crunchbase
The new targeted cancer drugs are not only safer but more effective than conventional cancer treatments because they are able to target and kill just diseased cells only.